Skip to main content

Advertisement

Log in

Pharmacokinetics of paclitaxel in an anephric patient

  • SHORT COMMUNICATION
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To assess the pharmacokinetics of paclitaxel for recurrent Wilms' tumor in an anephric pediatric patient receiving hemodialysis. Methods: Paclitaxel was administered at a dose of 250 mg/m2 and 350 mg/m2 by 24-h continuous intravenous (IV) infusion as two consecutive courses, respectively, separated by approximately 3 weeks. Paclitaxel plasma concentrations were measured by high-performance liquid chromatography (HPLC). Results: Paclitaxel disposition was comparable to that reported in similarly treated children with normal renal function. For the first course (250 mg/m2), paclitaxel concentrations were best fit by a two-compartment, first-order model. The calculated pharmacokinetic parameters were 0.312 h−1 for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h−1 and 0.105 h−1 for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 μM·h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl). The concentration-versus-time data with the second course (at the higher dosage of 350 mg/m2) were better described by a two-compartment model with saturable elimination. The calculated pharmacokinetic parameters were 12.0 μmol · h−1 for the maximal rate of elimination (Vm1−0), 0.158 μM for the concentration at which the rate of elimination is 50% of maximal (Km1−0), 0.809 h−1 for Kcp, 0.0792 h−1 for Kpc, 23.5 l/m2 for Vc, 20.9 μM·h for AUC, and 327 ml/min per m2 for Cl. Paclitaxel was undetectable in the dialysate. Conclusions: The level of systemic exposure in our anephric patient was comparable to or lower than that achieved in patients with normal renal function at similar dosages. The patient tolerated therapy without problems. It appears that pediatric patients in renal failure can be treated with paclitaxel as a 24-h continuous infusion at doses similar to those used in patients with normal renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 9 March 1998 / Accepted: 1 June 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

Woo, M., Gregornik, D., Shearer, P. et al. Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 43, 92–96 (1999). https://doi.org/10.1007/s002800050868

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800050868

Navigation